Compare YMAT & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YMAT | NXL |
|---|---|---|
| Founded | 1970 | 2010 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.5M |
| IPO Year | 2021 | 2022 |
| Metric | YMAT | NXL |
|---|---|---|
| Price | $1.82 | $0.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.6K | ★ 138.4K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $301,647.00 |
| Revenue This Year | N/A | $15.52 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | N/A | ★ 78.78 |
| 52 Week Low | $0.24 | $0.31 |
| 52 Week High | $2.94 | $2.00 |
| Indicator | YMAT | NXL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
J-Star Holding Co Ltd is engaged in the research, development, and manufacturing of carbon fiber for a wide variety-of-products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products. The company has five segments: Bicycle frame, Racket, Crank, Service provision, and Others. The majority of its revenue is generated from the Bicycle frame segment. Geographically, the company operates in Taiwan, China, and other regions.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.